… study, and led our FDA and EMA interactions regarding … of the first-ever treatment specific for postpartum depression. … Regulatory Affairs at Sunovion Pharmaceuticals (previously Sepracor) she led the … ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) …

… study, and led our FDA and EMA interactions regarding … of the first-ever treatment specific for postpartum depression. … Regulatory Affairs at Sunovion Pharmaceuticals (previously Sepracor) she led the … ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) …

… discoveries into commercially viable pharmaceutical products. Dr. Senanayake … at Dow Chemical, Merck, Sepracor, and Boehringer Ingelheim. He … his PhD and post-doctoral work in the US. … important drug candidates for the treatment of unmet medical needs …

… Product Commercialization at Sepracor, Inc., significantly contributing … held clinical-stage pharmaceutical company. Karim holds a … trials enrolling over 130 patients, including a Phase 2b trial … Drug status from the FDA and FDA/EMA, respectively. Medicenna’ …

… global clinical development and medical affairs organizations.  Throughout his … through the advancement of treatments in virology and the … with 54 ongoing clinical trials across virology, oncology, … such as 3v Biosciences, Sepracor, Regeneron and Merck. Under …

… Aralez Pharmaceuticals, Inc., Auxilium Pharmaceuticals, Inc., Enobia Pharma Corp., Sepracor Inc … He holds a Juris Doctorate and Master of Business … new drug application to the FDA for the treatment of … in clinical trials for the treatment of Stargardt …

… Silver Creek Pharmaceuticals, a clinical-stage biotechnology company focused … Development, at Sepracor. Prior to joining Sepracor, Dr. Corrigan … Clinical Research and Experimental Medicine. Dr. Corrigan serves … study for the treatment of acute ischemic stroke …

… -- Krouzon Pharmaceuticals, Inc., a biotechnology company focusing on … -doctoral research at the Yale School of Medicine … known pharmaceutical products for Boehringer Ingelheim Pharmaceuticals, Inc., Sepracor, Inc … s current drug candidate for the treatment of …

Sunovion Pharmaceuticals and two other subsidiaries … soon-to-be-combined Marlborough drugmaker Sumitomo Pharma America will … in November.   The Japanese drugmaker announced on April 3 it … release announcing the agreement. Sepracor changed its name to Sunovion …

… drug product for testing in clinical trials … known pharmaceutical products for Boehringer Ingelheim Pharmaceuticals, Inc., Sepracor, … Director at Shuttle Pharmaceuticals. Treatment with HDAC … Georgetown University Medical Center, Shuttle Pharmaceuticals is …